We rank companies based on fund manager, research analyst and news sentiment
FHTX stock icon

Foghorn Therapeutics Inc. Common Stock
FHTX

$7.42
7.25%
 

About: Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Employees: 116

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 4 analysts
0
News positive %
of 4 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

19% more capital invested

Capital invested by funds: $142M [Q3] → $169M (+$26.5M) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 18

3% less funds holding

Funds holding: 61 [Q3] → 59 (-2) [Q4]

6.04% less ownership

Funds ownership: 68.08% [Q3] → 62.04% (-6.04%) [Q4]

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$6
19%
downside
Avg. target
$13
75%
upside
High target
$20
170%
upside

4 analyst ratings

positive
75%
neutral
25%
negative
0%
Wedbush
Robert Driscoll
75%upside
$13
Outperform
Reiterated
10 Apr 2024
HC Wainwright & Co.
Andrew Fein
170%upside
$20
Buy
Reiterated
10 Apr 2024
Wedbush
Robert Driscoll
75%upside
$13
Outperform
Reiterated
8 Mar 2024
Morgan Stanley
Vikram Purohit
19%downside
$6
Equal-Weight
Maintained
13 Nov 2023

Financial journalist opinion

Based on 4 articles about FHTX published over the past 30 days